Urology Clinical Trials: Metastatic Urothelial Cancer (Upper Tract and Bladder)

Metastatic

1st Line
- Chemo vs Immunotherapy
- Post 1st Line Maintenance Immunotherapy

2nd Line and Above Targeted
- VICC URO 1723
  - An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and/or a TSC2 Mutation

2nd Line and Above Non-Targeted
- VICC PHI 1394
  - A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Metastatic Urothelial Cancer (UC) after Failure of First-Line Chemotherapy

*Please also refer to multi-disease flowchart for potential additional trials

KEY
- Accrual on hold
- Open

Team Leader Signature and Date